

Vitamin D and its Impact on Oral Health — An Update

SIDNEY H. STEIN, D.M.D., PH.D.

DAVID A. TIPTON, D.D.S., PH.D.

Introduction

Vitamin D plays a critical role in mediating calcium absorption and regulating musculoskeletal health.¹ It has also been demonstrated to function in the regulation of cardiovascular health, immune responses, wound healing and cancer prevention.²⁻⁶ Vitamin D is a fat soluble vitamin obtained from three sources. Endogenous synthesis of vitamin D occurs in the skin and is induced via ultraviolet radiation. It may also be obtained exogenously through dietary sources that include oily salt fish (mackerel, salmon, sardines and tuna), cod liver oil and egg yolk. Many countries, including the United States of America, fortify dairy products with vitamin D due to its scarcity in natural foods. Finally, various forms of vitamin D are available in over-the-counter dietary supplements. Vitamin D obtained through supplements is converted to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D through the same pathway that keratinocytes utilize when ultraviolet radiation stimulates its synthesis from a cholesterol precursor in the epidermis. The current recommended daily intake for vitamin D and calcium are 400-600 IU and 1,000 to 1,200 mg, respectively, for people over 50 years of age.⁷ Higher doses (800-1,000 IU) of vitamin D are recommended for osteoporosis prevention.⁸ It is estimated that 1 billion people worldwide have vitamin D deficiency.⁹⁻¹⁰

Effects of Vitamin D on Metabolism and Osteoporosis

As an important component of interactions among the kidney, bone, parathyroid gland and intestine, vitamin D helps to modulate skeletal and mineral homeostasis.¹ Through its role in maintaining proper extracellular calcium levels, vitamin D is essential in maintaining skeletal integrity. After its formation in the skin, via exposure to ultraviolet light and modification in the liver and kidney, vitamin D is released into the circulation. In plasma, it binds to carrier proteins which transport it

ABSTRACT

Vitamin D has been shown to regulate musculoskeletal health by mediating calcium absorption and mineral homeostasis. Evidence has demonstrated that vitamin D deficiency may place subjects at risk for not only low mineral bone density/osteoporosis and osteopenia but also infectious and chronic inflammatory diseases. Studies have shown an association between alveolar bone density, osteoporosis and tooth loss and suggest that low bone mass may be a risk factor for periodontal disease. Several recent reports demonstrate a significant association between periodontal health and the intake of vitamin D. An emerging hypothesis is that vitamin D may be beneficial for oral health, not only for its direct effect on bone metabolism but also due to its ability to function as an anti-inflammatory agent and stimulate the production of anti-microbial peptides.

CLINICAL SIGNIFICANCE:

The purpose of this review is to evaluate the impact of osteoporosis and vitamin D levels on periodontal health.

KEY-WORDS:

Vitamin D, osteoporosis, periodontal disease, innate immunity

to target organs and tissues.¹¹ Vitamin D then mediates its effects via binding to the vitamin D receptor (VDR), a member of the steroid superfamily receptors. Binding of vitamin D activates the VDR, which acts as a transcription factor for target genes.¹² Vitamin D increases the ability of the small intestine to absorb dietary calcium and phosphate. In intestinal epithelial cells, via binding and activation of the VDR, vitamin D stimulates calcium uptake and transport by upregulating expression of epithelial calcium channels, a cytosolic calcium binding protein, and plasma membrane proteins that mediate delivery of calcium to the bloodstream.¹³ By enhancing intestinal uptake of both calcium and phosphate, vitamin D helps to create optimum conditions for bone mineralization and is necessary for the development and maintenance of the mineralized skeleton.^{1,14}

Several molecules, including receptor activator of NF- κ B ligand (RANKL), and a RANKL antagonist (osteoprotegerin

or OPG) are produced by osteoblasts and other cells such as activated CD4+ T lymphocytes and are important regulators of bone remodeling.¹⁵⁻¹⁸ Binding of RANKL to RANK, expressed on the surface of osteoclast progenitor cells, causes them to differentiate into mature osteoclasts. OPG acts as a soluble receptor for RANKL, inhibiting RANK-RANKL interaction and the maturation of osteoclast progenitor cells. The relative ratio of RANKL to OPG in the osteoclast precursor microenvironment can thus determine mature osteoclast formation.

The RANKL gene promotor structure contains vitamin D and glucocorticoid response elements, and studies have shown that vitamin D-VDR stimulates RANKL expression in cells such as osteoblasts and bone marrow-derived stromal cells.¹⁹⁻²² Vitamin D has been shown to downregulate OPG, and this combination of increased RANKL expression and decreased expression of OPG caused by vitamin D would favor differentiation and activation

of osteoclasts and increased bone resorption.^{14,19,21-26} However, Hofbauer et al., have reported a stimulatory effect of vitamin D on OPG,²⁷ and Kondo et al., reported that while vitamin D initially represses OPG, long-term exposure to vitamin D led to a recovery of OPG expression.²⁴ This suggested that the catabolic effects of vitamin D can be transient. Indeed, vitamin D has several anabolic effects on osteoblasts, including stimulation of osteopontin and alkaline phosphatase, and in a rat model of osteoporosis, vitamin D also had anabolic effects.²⁸⁻³¹ Therefore, vitamin D appears to stimulate bone resorption (which is necessary for bone remodeling and formation of new bone), but after longer periods of exposure, it may facilitate osteoblast proliferation and differentiation.²⁴ Other studies have shown, however, that there is an association between lower serum vitamin D and increased expression of RANKL and other cytokines (i.e. IL-6 and TNF α) that stimulate osteoclastogenesis.³²⁻³⁴

Chronic low intake of Vitamin D and calcium leads to a negative calcium balance, impaired bone mineralization, and bone loss.³⁵ In children, vitamin D deficiency can cause rickets (characterized by limited growth and deformity of the long bones),³⁶⁻³⁸ while in adults, it can cause osteopenia and osteoporosis, as well as increase the risk of fracture.³⁹⁻⁴²

Osteoporosis and Periodontal Disease

Jabbar et al., have noted that, like periodontal disease, osteoporosis is a chronic, multifactorial disease and that the two diseases may share certain risk factors such as genetic polymorphisms and hormonal and/or dietary deficiencies.⁴³⁻⁴⁸ The contribution of generalized bone loss to oral bone loss and the extent of any relationship between osteoporosis and periodontal disease, however, is uncertain.^{49,50} Several studies have suggested an association between systemic bone mineral density/low bone mass/osteoporosis and alveolar bone density and tooth loss.^{48,51-77} However, data from some studies is difficult to accurately interpret and compare because of small sample sizes, insufficient control of confounding factors, different types of study populations and different methods or sites used to assess osteoporosis and periodontitis.⁴⁹ In addition, some studies

have presented evidence that bone mineral density is not related to alveolar bone loss. For example, Elders et al.,⁷⁸ found no significant relationship between systemic bone loss and alveolar bone height, concluding that systemic bone loss is not important in the pathogenesis of periodontitis. Klemetti et al.,⁷⁹ found no strong correlation between existing trabecular or cortical bone density and the rate of alveolar crestal bone loss. In a longitudinal study of 398 post menopausal women, Famili et al.,⁵⁰ found little evidence to support an association between edentulism, periodontal disease and longitudinal changes in bone mineral density. Researchers in this field have cited the need for additional larger scale, well-controlled studies to determine the role of osteopenia/osteoporosis on the prevalence and severity of periodontitis, as well as prospective studies to determine if osteopenia/osteoporosis is associated with the incidence and progression of periodontal disease.⁴⁹ Despite conflicting studies in the literature, however, Jeffcoat⁵² noted that most of the current evidence shows association between oral bone mineral density and some measure of systemic osteoporosis [i.e. dual energy x-ray absorption (DXA)]. This evidence suggests that osteoporosis/low bone mass may be a risk factor for periodontitis.^{49,54}

Vitamin D and Periodontal Health

There are conflicting reports regarding the benefit of vitamin D and calcium supplementation in the treatment of periodontal disease. Some earlier studies from the 1970's and 1980's suggested that reduced tooth loss and alveolar bone resorption were observed with calcium and vitamin D supplementation but were criticized for heterogenous composition of the study groups or because they did not measure periodontal disease status directly.⁸⁰⁻⁸³ More recent studies showed significant associations between periodontal health and intake of vitamin D and calcium,^{84,85} and that dietary supplementation with calcium and vitamin D may improve periodontal health, increase bone mineral density in the mandible and inhibit alveolar bone resorption.^{86,87} In a recently published longitudinal study, Garcia et al.,³⁵ reported that calcium and vitamin D supplementation may reduce the severity


of periodontal disease if used at doses higher than 800-1,000 IU daily and supported the rationale for testing the potential beneficial role of vitamin D on periodontal disease in randomized clinical trials. They also noted that vitamin D, in addition to its role in bone and calcium homeostasis, acts as an anti-inflammatory agent because it inhibits immune cell cytokine expression and causes monocyte/macrophages to secrete molecules that have a strong antibiotic effect.⁸⁸⁻⁹³ Indeed, vitamin D deficiency may be linked to increased risk of infectious diseases.⁹⁴ This suggests that vitamin D may be of benefit in the treatment of periodontitis, not only because of its direct effects on bone metabolism, but also because it may have antibiotic effects on periodontopathogens and inhibit inflammatory mediators that contribute to periodontal destruction.⁹⁵

Vitamin D and its Effects on Immune Responses

Vitamin D was implicated in the regulation of immune responses following the discovery of VDRs on most immune cells including activated CD4+ and CD8+ T cells, B cells, neutrophils and antigen presenting cells such as macrophages and dendritic cells.^{96,97} Vitamin D was also reported to exert pro-differentiation effects on monocytes, stimulating their acquisition of phenotypic features associated with macrophage.⁹⁸ In addition, vitamin D enhanced macrophage chemotactic and phagocytic capacity.⁹⁹ Vitamin D also inhibited the expression of monocytic inflammatory cytokines including IL-1, IL-6, TNF α , IL-8, and IL-12.¹⁰⁰⁻¹⁰² Recently, the antimicrobial effects of vitamin D were shown to be mediated via the VDR and associated with the upregulation of the cathelicidin hCAP-18 gene.¹⁰³ Importantly, toll like receptor activation of monocytes and macrophages results in the up-regulation of VDR and VDR target genes, with subsequent induction of cathelicidin antimicrobial peptide (CAMP) and killing of Mycobacterium tuberculosis.⁹² Besides CAMPs, beta defensins, which are a separate class of anti-microbial peptides, have also been identified as a direct target of vitamin D.¹⁰⁴ Another recent report demonstrated the physiological link between vitamin D mediated innate immunity and enhanced macrophage

phagocytosis induced by cathelicidins.¹⁰⁵ These findings support the active role of vitamin D in clearing bacterial infections through augmented production of anti-microbial peptides.

Conclusion

Historically, vitamin D has been shown to regulate musculoskeletal health by mediating calcium absorption. Evidence has demonstrated that vitamin D deficiency may place subjects at risk for low mineral bone density/osteoporosis and osteopenia, as well as infectious and chronic inflammatory diseases. A recently conducted longitudinal study lends support to the protective role of vitamin D in promoting oral health. An emerging hypothesis is that vitamin D may be of benefit in the treatment of periodontal disease, not only for its direct effect on bone metabolism but also due to its anti-inflammatory and CAMP-stimulating properties. 

Disclosure. None of the authors reported any disclosures.

References

1. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. *Am J Physiol* 2005; 289: F8-28.
2. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and Risk of Myocardial Infarction in Men. *Arch Intern Med* 2008; 168:1174-1180.
3. Kilkkinen A, Knekt P, Aro A, et al. Vitamin D Status and the Risk of Cardiovascular Disease death. *Am J Epidemiol* 2009; 170:1032-1039.
4. Gorham ED, Garland CF, Garland FC, et al. Optimal Vitamin D Status for Colorectal Cancer Prevention: A Quantitative Meta Analysis. *Am J Prev Med* 2007; 32:210-216.
5. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA. Vitamin D Intake and the Risk for Pancreatic Cancer in Two Cohort Studies. *Cancer Epidemiol Biomarkers Prev* 2006; 15:1688-1695.
6. Giovannucci E, Liu Y, Rimm EB et al. Prospective Study of Predictors for Vitamin D Status and Cancer Incidence and Mortality in Men. *J Natl Cancer Inst* 2006; 98:451-459.
7. Moore C, Murphy MM, Keast DR, Holick MF. Vitamin D Intake in the United States. *J Am Diet Assoc* 2004; 104:980-983.
8. National Osteoporosis Foundation. NOF Recommendations for Vitamin D. Available at <http://www.nof.org/prevention/vitaminD.htm>. Accessed June 2, 2010.
9. Glerup H, Mikkelsen K, Poulsen L et al. Commonly Recommended Daily Intake of Vitamin D is Not Sufficient if Sunlight Exposure is Limited. *J Intern Med* 2000; 247:260-268.
10. Holick MF. Resurrection of Vitamin D Deficiency and Rickets. *J Clin Invest* 2006; 116:2062-2072.
11. Cooke NE, Haddad JG. Vitamin D Binding Protein (G-globulin). *Endocr Rev* 1989; 10: 294-307.
12. Brown AJ, Dusso A, and Slatopolsky E. Vitamin D. *Am J Physiol Renal Physiol* 1999; 277: F157-F175.
13. Bouillon R, Van Cromphaut S, and Carmeliet G. Intestinal Calcium Absorption: Molecular Vitamin D Mediated Mechanisms. *J Cell Biochem* 2003; 88: 332-339.
14. Andresen C, Olson E, Nduaka C, Pero R, Bagi CM. Action of Calcitropic Hormones on Bone Metabolism – Role of Vitamin D3 in Bone Remodeling Events. *Am J Immunol* 2006; 2: 40-51.
15. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin Ligand

is a Cytokine That Regulates Osteoclast Differentiation and Activation. *Cell* 1998; 93: 165-176.

16. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-Related Activation-induced Cytokine), a New TNK Family Member Predominantly Expressed in T Cells, is a Dendritic Cell-specific Survival Factor. *J Exp Med* 1997; 186: 2075-2080.
17. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is Produced by Osteoblasts and Induces Bone Resorption. *J Immunol* 1990; 145: 3297-3303.
18. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a Key Regulator of Osteoclastogenesis, Lymphocyte Development and Lymph-node Organogenesis. *Nature* 1999; 397: 315-323.
19. Kitazawa S, Kajimoto K, Kondo T, and Kitazawa R. Vitamin D3 Supports Osteoclastogenesis Via Functional Vitamin D Response Element of Human RANKL Gene Promoter. *J Cell Biochem* 2003; 89: 771-777.
20. Kitazawa R, Kitazawa S, Maeda S. Promotor Structure of Mouse RANKL/TRANCE/OPGL/ODF gene. *Biochim Biophys Acta* 1999; 1445: 134-141.
21. Horwood N, Elliott J, Martin T, Gillespie M. Osteotropic Agents Regulate the Expression of Osteoclast Differentiation Factor and Osteoprotegerin in Osteoblastic Stromal Cells. *Endocrinol* 1998; 139: 4743-4746.
22. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I, et al. Osteoclast Differentiation Factor is a Ligand for Osteoprotegerin/osteoclastogenesis Inhibitory Factor and is Identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* 1998; 95: 3597-3602.
23. Murakami T, Yamamoto M, Yamamoto M, et al. Transforming Growth factor- β 1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/stromal Cells and Inhibits the Survival of Murine Osteoclast-like Cells. *Biochem Biophys Res Commun* 1998; 252: 747-752.
24. Kondo T, Kitazawa R, Maeda S, and Kitazawa S. 1,25 Dihydroxyvitamin D3 Rapidly Regulates the Mouse Osteoprotegerin Gene Through Dual Pathways. *J Bone Miner Res* 2004; 19: 1411-1419.
25. Hofbauer L, Huefelder A. The Role of Receptor Activator of Nuclear Factor- κ B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. *J Endocrinol Metab* 2000; 85: 2355-2363.
26. Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-ishi A, Sato K, Kubodera N, Ikeda K, Ogata E. ED-71, A Vitamin D Analog, is a More Potent Inhibitor of Bone Resorption Than Alfacalcidol in an Estrogen-deficient Rat Model of Osteoporosis. *Bone* 2002; 30: 582-588.
27. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin Production by Human Osteoblast Lineage Cells is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines. *Biochem Biophys Res Commun* 1998; 250: 77-781.
28. Erben RG, Bromm S, Stangassinger M. Therapeutic Efficacy of 1 α ,25-Dihydroxyvitamin D3 and Calcium in Osteopenic Ovariectomized Rats: Evidence for a Direct Anabolic Effect of 1 α ,25-dihydroxyvitamin D3 on Bone. *Endocrinol* 1998; 139:4319-4328.
29. Wang DS, Miura M, Demura H, Sato K. Anabolic Effects of 1,25-Dihydroxyvitamin D3 on Osteoblasts are Enhanced by Vascular Endothelial Growth Factor Produced by Osteoblasts and by Growth Factors Produced by Endothelial Cells. *Endocrinol* 1997;138: 2953-2962.
30. Farach-Carson MC. Bioactive Analogs That Simulate Subsets of Biological Activities of 1 α ,25(OH)2D3 in Osteoblasts. *Steroids* 2001; 66: 357-361.
31. Erben RG, Scutt AM, Miao D, Kollenkirchen U, Haberey M. Short-term Treatment of Rats with High Dose 1,25-dihydroxyvitamin D3 Stimulates Bone Formation and Increases the Number of Osteoblast Precursor Cells in Bone Marrow. *Endocrinol* 1997; 138: 4629-4635.
32. Nonn L, Peng L, Feldman D, Peeh D. Inhibition of p38 by Vitamin D Reduces Interleukin-6 Production in Normal Prostate Cells Via Mitogen-activated Protein Kinase Phosphatase 5: Implications for Prostate Cancer Prevention by Vitamin D. *Cancer Res* 2006; 66: 4516-4524.
33. Peterson CA, Heffernan ME. Serum Tumor Necrosis Factor- α Concentrations are Negatively Correlated with Serum 25(OH)D Concentrations in Healthy Women. *J Inflamm* 2008; 81: 353-373.
34. Anderson PH, Moore AJ, May BK, O'Loughlin PD, Morris HA. Vitamin D Depletion Induces RANKL-mediated Osteoclastogenesis and Bone Loss in a Rodent Model. *J Bone Miner Res* 2008; 23: 1789-1797.
35. Garcia M, Hildebolt C, Miley D, et al. One-year Effects of Vitamin D and Calcium Supplementation on Chronic

Periodontitis. *J Periodontol* 2011; 82: 25-32.

36. Holick MF. Resurrection of Vitamin D Deficiency and Rickets. *J Clin Invest* 2006; 116: 2062-72.
37. Hess AF. Collected writings, volume I. Springfield, IL: Charles C Thomas, 1936: 669-719.
38. Hess AF, Unger LJ. The Cure of Infantile Rickets by Sunlight. *JAMA* 1921; 77: 39.
39. Holick MF. Vitamin D Deficiency. *N Engl J Med* 2007; 357: 266-81.
40. Chapuy MC, Schott AM, Garnero P, Hans D, Delmas PD, Meunier J. Healthy Elderly French Women Living at Home Have Secondary Hyperparathyroidism and High Bone Turnover in Winter. *J Clin Endocrinol Metab* 1996; 81: 1129-33.
41. Bakhtiyarova S, Lesnyak O, Kyznesova N, Blankenstein MA, Lips P. Vitamin D Status Among Patients with Hip Fracture and Elderly Control Subjects in Yekaterinburg, Russia. *Osteoporos Int* 2006; 17: 441-6.
42. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and Calcium Supplementation Prevents Osteoporotic Fractures in Elderly Community Dwelling Residents: A Pragmatic Population-based 3-year Intervention Study. *J Bone Miner Res* 2004; 19: 370-8.
43. Jabbar S, Drury J, Fordham J, Datta H, Francis R, Tuck S. Plasma Vitamin D and Cytokines in Periodontal Disease and Postmenopausal Osteoporosis. *J Periodont Res* 2011; 46: 97-104.
44. Jonhson RB, Gilbert JA, Cooper RC et al. Effect of Estrogen Deficiency on Skeletal and Alveolar Bone Density in Sheep. *J Periodontol* 2002; 73: 383-391.
45. Sun JL, Meng HX, Cao CF, Tachi Y, Shinohara M, Ueda M. Relationship Between Vitamin D Receptor Gene Polymorphism and Periodontitis. *J Periodont Res* 2002; 37: 263-267.
46. Taguchi A, Kobayashi J, Sueti Y, Ohtsuka M, Nakamoto T, Tanimoto K. Association of Estrogen and Vitamin D Receptor Gene Polymorphisms with Tooth Loss and Oral Bone Loss in Japanese Postmenopausal Women. *Menopause* 2003; 10: 250-257.
47. de Brito Junior RB, Scarel-Caminaga RM, Trevisatto PC, de Souza AP, Barros SP. Polymorphisms in the Vitamin D Receptor Gene are Associated with Periodontal Disease. *J Periodontol* 2004; 75: 1090-1095.
48. Taguchi A, Sanada M, Sueti Y. Effect of Estrogen Use on Tooth Retention, Oral Bone Height and Oral Bone Porosity in Japanese Postmenopausal Women. *Menopause* 2004; 11: 556-562.
49. Tezal M, Wactawski-Wende J, Grossi SG, Ho AW, Dunford R, Genco RJ. The Relationship Between Bone Mineral Density and Periodontitis in Postmenopausal Women. *J Periodontol* 2000; 71: 1492-1498.
50. Famili P, Cauley J, Suzuki JB, Weyant R. Longitudinal Study of Periodontal disease and Edentulism with Rates of Bone Loss in Older Women. *J Periodontol* 2005; 76: 11-15.
51. Hildebolt CF. Osteoporosis and Oral Bone Loss. *Dentomaxillofac Radiol* 1997; 26: 3-15.
52. Jeffcoat M. The Association Between Osteoporosis and Oral Bone Loss. *J Periodontol* 2005; 76(Suppl. 11): 2125-2132.
53. Jeffcoat MK, Reddy MS. Alveolar Bone Loss Andosteoporosis: Evidence for a Common Mode of Therapy Using the Bisphosphonate Alendronate. In: Davidovitch Z, Norton L, eds. *The Biologic Mechanism of Tooth Resorption and Replacement by Implants*. Boston: Harvard Society for the Advancement of Orthodontics; 1996: 365-373.
54. Payne JB, Reinhardt RA, Nummikoski PV, Patil KD. Longitudinal Alveolar Bone Loss in Postmenopausal Osteoporotic/osteopenic Women. *Osteoporos Int* 1999; 10: 34-40.
55. Southard KA, Southard TE, Schlechte JA, Meis PA. The Relationship Between the Density of the Alveolar Processes and that of Post-cranial Bone. *J Dent Res* 2000; 79: 964-969.
56. Wactawski-Wende J, Grossi SG, Trevisan M, et al. The Role of Osteopenia in Oral Bone Loss and Periodontal Disease. *J Periodontol* 1996; 67(Suppl. 10):1076-1084.
57. Wactawski-Wende J, Hausmann E, Hovey K, Trevisan M, Grossi S, Genco RJ. The Association Between Osteoporosis and Alveolar Crestal Height in Postmenopausal Women. *J Periodontol* 2005; 76(Suppl. 11): 2116-2124.
58. Walters MR. Newly Identified Actions of the Vitamin D Endocrine System. *Endocr Rev* 1992; 13: 719-764.
59. Lundstrom A, Jendle J, Stenstrom B, Toss G, Ravald N. Periodontal Conditions in 70-year-old Women with Osteoporosis. *Swed Dent J* 2001; 25 :89-96.

60. Osterberg T, Lerner UH, Johnell O, Mellstrom D. Relation Between Previous Fracture and Loss of Teeth Independent of Bone Mineral Density: A Population Study of 567 70-year-old Women. *J Bone Miner Res* 2003; 18(Suppl 1): #SU281.
61. Mohammad AR, Hooper DA, Vermilyea SG, Mariotti A, Preshaw PM. An Investigation of the Relationship Between Systemic Bone Density and Clinical Periodontal Status in Post-menopausal Asian-American Women. *Int Dent J* 2003; 53: 121-125.
62. Gur A, Nas K, Kayhan O, Atay MB, Akyuz G, Sindal D. The Relation Between Tooth Loss and Bone Mass in Postmenopausal Osteoporotic Women in Turkey: A Multicenter Study. *J Bone Miner Metab* 2003; 21: 43-47.
63. Takaishi Y, Okamoto Y, Ikee T. Correlations Between Periodontitis and Loss of Mandibular Bone in Relation to Systemic Bone Changes in Postmenopausal Japanese Women. *Osteoporos Int* 2005; 16: 1875-1882.
64. Nicopoulou-Karayianni K, Tzoutzoukos P, Karayiannis A. Tooth Loss and Osteoporosis: the Osteodent Study. *J Clin Periodontol* 2009; 36: 190-197.
65. Yoshihara A, Seida Y, Hanada N. The Relationship Between Bone Mineral Density and the Number of Remaining Teeth in Community-dwelling Older Adults. *J Oral Rehabil* 2005; 32: 735-740.
66. Inagaki K, Kurosu Y, Yoshinara N et al. Efficacy of Periodontal Disease and Tooth Loss to Screen for Low Bone Mineral Density in Japanese Women. *Calcif Tissue Int* 2005; 77: 9-14.
67. Brennan RM, Genco RJ, Hovey KM. Clinical Attachment Loss, Systemic Bone Density, and Gingival Calculus in Postmenopausal Women. *J Periodontol* 2007; 78: 2104-2111.
68. Yoshihara A, Seida Y, Hanada N, Miyazaki H. A Longitudinal Study of the Relationship Between Periodontal Disease and Bone Mineral Density in Community Dwelling Older Adults. *J Clin Periodontol* 2004; 31: 680-684.
69. Kribbs PJ, Smith DE, Chesnut CH. Oral Findings in Osteoporosis. Part II: Relationship Between Residual Ridge and Alveolar Bone Resorption and Generalized Skeletal Osteopenia. *J Prosthet Dent* 1983; 50: 719-724.
70. Kribbs PJ, Chesnut CH, Ott SM, Kilcoyne RF. Relationships Between Mandibular and Skeletal Bone in an Osteoporotic Population. *J Prosthet Dent* 1989; 62: 703-707.
71. Kribbs PJ. Comparison of Mandibular Bone in Normal and Osteoporotic Women. *J Prosthet Dent* 1990; 63: 218-222.
72. Jacobs R, Ghyssels J, Koninckx P, van Steenberghe D. Long-term Bone Mass evaluation of Mandible and Lumbar Spine in a Group of Women Receiving Hormone Replacement Therapy. *Eur J Oral Sci* 1996; 104: 10-16.
73. von Wöwern N, Klausen B, Kollerup G. Osteoporosis: A Risk Factor in Periodontal Disease. *J Periodontol* 1994; 65: 1134-1138.
74. Streckfus CF, Johnson RB, Nick T, Tsao A, Tucci M. Comparison of Alveolar Bone Loss, Alveolar Bone Density and Second Metacarpal Bone Density, Salivary and Gingival Crevicular Fluid Interleukin-6 Concentrations in Healthy Premenopausal and Postmenopausal Women on Estrogen Therapy. *J Gerontol A Biol Sci Med Sci* 1997; 52: M343-M351.
75. Jeffcoat MK, Lewis CE, Reddy MS, Wang C-Y, Redford M. Post-menopausal Bone Loss and Its Relationship to Oral Bone Loss. *Periodontol* 2000 2000; 23: 94-102.
76. Hildebolt CF, Pilgram TK, Yokoyama-Crothers N, et al. The Pattern of Alveolar Crest Height Change in Healthy Postmenopausal Women After 3 Years of Hormone/estrogen Replacement Therapy. *J Periodontol* 2002; 73: 1279-1284.
77. Geurs NC, Lewis CE, Jeffcoat MK. Osteoporosis and Periodontal Disease Progression. *Periodontol* 2000 2003; 32: 105-110.
78. Elders PJM, Habets LLMH, Netelenbos JC, van der Linden LWJ, van der Stelt PF. The Relation Between Periodontitis and Systemic Bone Mass in Women Between 46 and 55 Years of Age. *J Clin Periodontol* 1992; 19: 492-496.
79. Klemetti E, Väinö P, Lassila V, Alhava E. Trabecular Bone Mineral Density of Mandible and Alveolar Height in Postmenopausal Women. *Scand J Dent Res* 1993; 101:166-170.
80. Baxter JC. The Nutritional Intake of Geriatric Patients with Varied Dentitions. *J Prosthet Dent* 1984; 51: 164-168.
81. Renner RP, Boucher LJ, Kaufman HW. Osteoporosis in Postmenopausal Women. *J Prosthet Dent* 1984; 52: 581-588.
82. Wical KE, Brussee P. Effects of a Calcium and Vitamin D Supplement on Alveolar Ridge Resorption in Immediate Denture Patients. *J Prosthet Dent* 1979; 41: 4-11.
83. Wical KE, Swoope CC. Studies of Residual Ridge Resorption. II. The Relationship of Dietary Calcium and Phosphorus to Residual Ridge Resorption. *J Prosthet Dent* 1974; 32: 13-22.
84. Dietrich T, Josphura KJ, Dawson-Hughes B, Bischoff-Ferrari HA. Association Between Serum Concentrations of 25-hydroxyvitamin D3 and Periodontal Disease in the US Population. *Am J Clin Nutr* 2004; 80: 108-113.
85. Nishida M, Grossi SG, Dunford RG, Ho AW, Trevisan M, Genco RJ. Calcium and the Risk for Periodontal Disease. *J Periodontol* 2000; 71: 1057-1066.
86. Hildebolt CF, Pilgram TK, Dotson M, Armamento-Villareal R, Hauser J, Cohen S. Estrogen and/or Calcium Plus Vitamin D Increase Mandibular Bone Mass. *J Periodontol* 2004; 75: 811-816.
87. Miley DD, Garcia MN, Hildebolt CF. Cross-sectional Study of Vitamin D and Calcium Supplementation Effects on Chronic Periodontitis. *J Periodontol* 2009; 80: 1433-1439.
88. Walters MR. Newly Identified Actions of the Vitamin D Endocrine System. *Endocr Rev* 1992; 13: 719-764.
89. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and Treatment of Vitamin D Deficiency. *Expert Opin Pharmacother* 2008a; 9: 107-118.
90. Cannell JJ, Vieth R, Willett W, et al. Cod liver oil, Vitamin A Toxicity, Frequent Respiratory Infections, and the Vitamin D Deficiency Epidemic. *Ann Otol Rhinol Laryngol* 2008c; 117: 864-870.
91. Dale BA, Kimball JR, Krisanaprakornkit S, et al. Localized Antimicrobial Peptide Expression in Human Gingiva. *J Periodontol Res* 2001; 36: 285-294.
92. Liu PT, Stenger S, Li H, et al. Toll-like Receptor Triggering of a Vitamin D-mediated Human Antimicrobial Response. *Science* 2006; 311: 1770-1773.
93. White JH. Vitamin D Signaling, Infectious Diseases, and Regulation of Innate Immunity. *Infect Immun* 2008; 76: 3837-3843.
94. Zittermann A. Vitamin D in Preventive Medicine: Are We Ignoring the Evidence? *Br J Nutr* 2003; 89: 552-572.
95. Cochran DL. Inflammation and Bone Loss in Periodontal Disease. *J Periodontol* 2008; 79(Suppl.8): 1569-1576.
96. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 Receptors in Human Leukocytes. *Science* 1983; 221 1181-1183.
97. Takahashi K, Nakayama Y, Horiuchi H, et al. Human Neutrophils Express Messenger RNA of Vitamin D Receptor and Respond to 1 α ,25-dihydroxyvitamin D3. *Immunopharmacol Immunotoxicol* 2002; 24:335-347.
98. Griffin MD, Xing N, Kumar R. Vitamin D and Its Analogs as regulators of Immune Activation and Antigen Presentation. *Annu Rev Nutr* 2003; 23:117-145.
99. Xu H, Soruri A, Gieseler RK, Peters JH. 1,25-Dihydroxyvitamin D3 Exerts Opposing Effects to IL-4 on MHC Class-II Antigen Expression, Accessory Activity, and Phagocytosis of Human Monocytes. *Scand J Immunol* 1993; 38:535-540.
100. Almerighi D, Sinistro A, Cavazza A, Ciapriani C, Rocchi G, Bergamini A. 1 α ,25-dihydroxyvitamin D3 Inhibits CD40L-induced Pro-inflammatory and Immunomodulatory Activity in Human Monocytes. *Cytokine* 2009; 45:190-197.
101. D'Ambrosio D, Cippitelli M, Coccio MG, et al. Inhibition of IL-12 Production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB Downregulation in Transcriptional Repression of the p40 Gene. *J Clin Invest* 1998; 101:252-262.
102. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes From Type 2 Diabetic Patients Have a Pro-inflammatory Profile. 1,25-Dihydroxyvitamin D(3) Works as an Anti-inflammatory. *Diabetes Res Clin Pract* 2007; 77:47-57.
103. Martineau AR, Wilkinson KA, Newton SM, et al. IFN-gamma and TNF-Independent Vitamin D-inducible Human Suppression of Mycobacteria: The Role of Cathelicidin LL-37. *J Immunol* 2007; 178:7190-7198.
104. Wang TT, Nestel FP, Bourdeau V, et al. Cutting Edge: 1,25-dihydroxyvitamin D3 is a Direct Inducer of the Antimicrobial Peptide Gene Expression. *J Immunol* 2004;173:2909-2912.
105. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 Induces Autophagy in Human Monocytes via Cathelicidin. *Cell Host Microbe* 2009; 6:231-143.

*Sidney H. Stein, D.M.D., Ph.D.,
Associate Professor Department of
Periodontology, College of Dentistry,
University of Tennessee Health Science
Center in Memphis, Tennessee.*

*David A. Tipton, D.D.S., Ph.D.,
Professor Department of Bioscience
Research, College of Dentistry, University
of Tennessee Health Science Center in
Memphis, Tennessee.*

Questions for Continuing Education Article - CE Exam #29

1. Vitamin D has been shown to regulate musculoskeletal health by mediating:
 - a. Striated muscle formation
 - b. Fat absorption
 - c. Co-Q-10
 - d. Calcium absorption
2. An emerging hypothesis is that Vitamin D may be beneficial for oral health due to its:
 - a. Anti-inflammatory properties
 - b. Stimulation of the production of anti-microbial peptides
 - c. a. and b.
 - d. None of the above
3. The current recommendation for the daily intake of Vitamin D is:
 - a. 250-500 mg.
 - b. 400-600 IU
 - c. 1000-2000 mg.
 - d. 3000-5000 mg.
4. Chronic low intake of Vitamin D and calcium leads to a:
 - a. Negative calcium balance
 - b. Impaired bone mineralization
 - c. Bone loss
 - d. All the above
5. Recent studies showed a significant association between intake of Vitamin D and Calcium and:
 - a. Periodontal health
 - b. Kidney stones
 - c. Decreased olfaction
 - d. Benign migratory glossitis


Publication date: Spring 2011. Expiration date: Spring 2014.

Answer Form for TDA CE Credit Exam #29:

Vitamin D and its Impact on Oral Health — An Update

Publication date: Spring 2011. Expiration date: Spring 2014.

Circle the correct letter answer for each CE Exam question:



1.	a	b	c	d
2.	a	b	c	d
3.	a	b	c	d
4.	a	b	c	d
5.	a	b	c	d

Cost per exam per person is \$15.00 for one (1) continuing education credit.
This page may be duplicated for multiple use. Please print or type.

ADA ID Number (Dentist Only): _____

License Number of RDH: _____

Registration Number if RDA: _____

Name (Last/First/Middle): _____

Office Address: _____

City/State/Zip: _____

Daytime Phone Number : (_____) _____

Component Society (TDA Member Only): _____

Dr. _____

(Auxiliary Staff: Please provide name of Employer Dentist)

All checks should be made payable to the Tennessee Dental Association. Return the Exam Form and your check or credit card information to:

Tennessee Dental Association at 660 Bakers Bridge Ave., Suite 300 in Franklin, TN 37067

The form may be faxed to 615-628-0214 if using a credit card.

Credit Card Information (Use your TDA/Bank of America card, MasterCard or Visa ONLY):

Signature: _____

Card #: _____ Exp. Date: _____

Three-digit CVV2 Code (on back of the card following the card number): _____

Name as it appears on the card: _____

Do not write in this space - for TDA Administration purposes only

Check #: _____

CC

Paid w/doctor's CC